rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The L858R mutation was significantly correlated with gender (women versus men, P < 0.0001), Brinkman index (600 < or = versus 600, P = 0.001), pathologic subtypes (adenocarcinoma versus nonadenocarcinoma, P = 0.007), and differentiation status of the lung cancers (well versus moderately or poorly, P = 0.0439), whereas the deletion mutants were not.
|
15837743 |
2005 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas.
|
16705038 |
2006 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Herein, we report a case of 2 synchronous lung adenocarcinomas composed of 2 distinct pathological subtypes with different EGFR mutations: homozygous deletion in exon 19 in the papillary subtype of adenocarcinoma and a point mutation of L858R in exon 21 in the tubular adenocarcinoma.
|
18186961 |
2007 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this prospective study, EGFR exon 19 deletion or L858R mutations in adenocarcinoma were the best predictors for longer TTF in stage IIIB/IV chemotherapy-naive NSCLC patients receiving first-line gefitinib monotherapy.
|
18509184 |
2008 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In particular, 3 of 4 adenocarcinomas with EGFR mutations (all L858R point mutations in women, never or former smokers) had a concomitant and identical mutation in AAH, and 2 of 4 adenocarcinomas with K-ras mutations (both at codon 12 in women, a never and a current smoker) showed the same mutation in concomitant AAH.All cases were wild-type for HER2.
|
18208799 |
2008 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Pulmonary adenocarcinoma tissue from 20 previously genotyped specimens was prepared for immunohistochemical staining by two antibodies that recognise products of in-frame deletions in exon 19 (E746_A750del) and a point mutation that replaces leucine with arginine at codon 858 in exon 21 (L858R) of the EGFR gene.
|
21187519 |
2010 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Plasma DNA samples from 73 patients with stage IIIB to IV adenocarcinoma were analyzed for EGFR mutations in exons 19 (deletion mutation) and 21 (L858R mutation) using direct DNA sequencing, DHPLC and Scorpions ARMS.
|
21518597 |
2011 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Analyses of the EGFR mutation in separately microdissected specimens from adenocarcinoma and spindle cell components revealed that both components possessed the L858R point mutation.
|
21556797 |
2011 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Seven adenocarcinoma components were EGFR mutated: five exon 19 deletions and two mutations in exon 21 (L833_V834delinsFL and L858R).Four SCLC components were EGFR mutated.
|
24457237 |
2013 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Twenty-six patients were enrolled, all of whom were diagnosed with adenocarcinoma with EGFR mutations (19del: 16, L858R: 10) except one (squamous cell carcinoma with 19del).
|
24369725 |
2013 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the ADC/BAC group, KRAS mutations were more frequent in man (P<0.02) and EGFR mutations (exon 19 deletion and L858R) demonstrated a tendency towards worse disease-free survival (P=0.056).
|
23357969 |
2014 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Pretreatment evaluation of EGFR mutations in the resected primary adenocarcinoma specimen showed an L858R mutation in exon 21.
|
24852875 |
2014 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Finally, we showed that EGFR(L858R)/Rhob(+/+) mice developed mainly diffuse lung tumors with a lepidic pattern, whereas EGFR(L858R)/Rhob(+/-) and EGFR(L858R)/Rhob(-/-) developed a greater number of tumors, and aggressive adenocarcinomas with invasive properties.
|
25320360 |
2014 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In multivariate analysis, adenocarcinoma (hazard ratio, HR, 12.25; 95% CI, 37.7-41.10; p < 0.001) and major mutations (deletions in exon 19 and L858R point mutation in exon 21; HR, 2.46; 95% CI, 1.14-5.28; p = 0.022) were significant predictors of longer PFS.
|
24457318 |
2014 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We report here a case of pulmonary adenocarcinoma with concomitant EGFR mutation in exon 21 (L858R) and ALK rearrangement in naive and relapsed tumors.
|
25312989 |
2014 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Eighteen out of 20 large cell carcinomas, not otherwise specified, had glandular differentiation upon immunohistochemistry, with an exon 21 L858R EGFR mutation in one (5 %) tumor, an exon 2 KRAS mutation in eight (40 %) tumors, and an ALK translocation in one (5 %) tumor, whereas two tumors positive for CK7 and CK5/6 and negative for all other markers were considered adenocarcinoma.
|
24221342 |
2014 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
IHC was performed using mutation-specific antibodies for E746-A750 deletion (DEL) and L858R point mutation (L858R) in biopsies and tissue microarrays of resected tumors from 154 patients with pulmonary adenocarcinoma.
|
25687872 |
2015 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All tumors had adenocarcinoma histology, and 20 patients (62.5 %) had an L858R mutation.
|
26003540 |
2015 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR mutations (ex19del and L858R) were detected in 1759/8716 (20.2 %) adenocarcinomas, 28/669 (4.2 %) squamous cell carcinomas (SCC) and 8/119 (6.7 %) large cell carcinomas.
|
27259329 |
2016 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
No significant differences in pathological stage and metastasis status were found between EGFR wild-type and mutated cases, although EGFR mutation type was related to pathological type (p=0.00) - 19-del, L858R and other mutation types respectively occurred in 34.2%, 42.5% and 23.3% of adenocarcinomas, but in 14.3%, 0% and 85.7% of non-adenocarcinomas.
|
27039821 |
2016 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We demonstrated that adenocarcinomas with L858R mutation, rather than exon 19 deletion or wild-type EGFR gene, prefer to locate over the upper lungs.
|
26645716 |
2016 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Advanced unresectable pulmonary adenocarcinoma with the epidermal growth factor receptor (EGFR) exon 21 L858R point mutation (Ex21) is associated with a poor prognosis.
|
27553497 |
2016 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although 19-deletion and L858R were the most common EGFR mutations, there was no difference of EGFR mutation in pathological subtypes of adenocarcinoma.
|
27032467 |
2016 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor (EGFR) mutations (ie, exon 19 deletions and exon 21 L858R substitution) and anaplastic lymphoma kinase (ALK) rearrangements in advanced non-small-cell lung cancers of adenocarcinoma histology, with the intent of permitting use of these predictive biomarkers to select patients who will derive maximal benefit from approved oral tyrosine kinase inhibitors (TKIs) directed against EGFR and ALK, respectively.
|
27381270 |
2016 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 44-year-old male, never smoker, suffers from stage IV adenocarcinoma of the right lung with epidermal growth factor receptor (EGFR) exon-21 L858R point mutation on initial presentation.
|
28296233 |
2017 |